| Literature DB >> 28708825 |
Upendo Mwingira1,2, Maria Chikawe1,2, Wilfred Lazarus Mandara1, Hayley E Mableson3, Cecilia Uisso1, Irene Mremi1, Alpha Malishee1, Mwele Malecela2, Charles D Mackenzie3,4, Louise A Kelly-Hope3, Michelle C Stanton3.
Abstract
BACKGROUND: Lymphatic filariasis (LF) is best known for the disabling and disfiguring clinical conditions that infected patients can develop; providing care for these individuals is a major goal of the Global Programme to Eliminate LF. Methods of locating these patients, knowing their true number and thus providing care for them, remains a challenge for national medical systems, particularly when the endemic zone is a large urban area. METHODOLOGY/PRINCIPLEEntities:
Mesh:
Year: 2017 PMID: 28708825 PMCID: PMC5529014 DOI: 10.1371/journal.pntd.0005748
Source DB: PubMed Journal: PLoS Negl Trop Dis ISSN: 1935-2727
Fig 1Flow of patient information during the patient identification exercise conducted in the three districts of Dar es Salaam.
Reported lymphoedema-elephantiasis and hydrocoele prevalence for each of Dar es Salaam’s three districts.
| Lymphoedema-Elephantiasis only | Hydrocoele only | Both | Total | |||||
|---|---|---|---|---|---|---|---|---|
| N | Prevalence per 100,000 total population | N | Prevalence per 100,000 total population (per 100,000 male population) | N | Prevalence per 100,000 total population | N | Prevalence per 100,000 total population | |
| 807 | 49.8 | 1560 | 96.2 (220.4) | 183 | 11.3 | 2550 | 157.3 | |
| 950 | 46.4 | 1654 | 80.7 (183.2) | 242 | 11.8 | 2846 | 138.9 | |
| 494 | 33.3 | 955 | 64.3 (150.5) | 44 | 3.0 | 1493 | 100.5 | |
Demographic summaries of reported patients.
| Lymphoedema-Elephantiasis (include both conditions) | Hydrocoele | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Male | Female | Total | Male Total | ||||||
| N | Prevalence per 100,000 total population | N | Prevalence per 100,000 total population | N | Prevalence per 100,000 total population | N | Prevalence per 100,000 total population (per 100,000 males) | ||
| 1 | 0.42 | 5 | 2.05 | 6 | 1.25 | 23 | 4.8 (9.7) | ||
| 37 | 16.39 | 66 | 24.40 | 103 | 20.76 | 124 | 25.0 (54.9) | ||
| 116 | 73.41 | 167 | 111.15 | 283 | 91.80 | 532 | 172.6 (336.7) | ||
| 138 | 226.85 | 148 | 285.56 | 286 | 253.86 | 521 | 462.4 (856.4) | ||
| 113 | 534.94 | 104 | 618.50 | 217 | 571.97 | 408 | 1075.4 (1931.4) | ||
| 52 | 917.48 | 39 | 543.37 | 91 | 708.44 | 131 | 1019.8 (2311.3) | ||
| 2 | - | 2 | 4 | 4 | |||||
| 18 | 6.58 | 6 | 2.12 | 24 | 4.31 | 57 | 10.2 (20.8) | ||
| 66 | 21.74 | 52 | 13.69 | 118 | 17.27 | 165 | 24.1 (54.3) | ||
| 206 | 95.25 | 204 | 102.19 | 410 | 98.58 | 635 | 152.7 (293.6) | ||
| 171 | 224.21 | 177 | 263.27 | 348 | 242.51 | 593 | 413.2 (777.5) | ||
| 122 | 451.83 | 110 | 502.00 | 232 | 474.30 | 356 | 727.8 (1318.5) | ||
| 29 | 474.44 | 30 | 400.88 | 59 | 433.95 | 88 | 647.2 (1439.7) | ||
| 1 | - | 0 | - | 1 | 2 | - | |||
| 3 | 1.45 | 1 | 0.47 | 4 | 0.96 | 25 | 6.0 (12.1) | ||
| 27 | 13.42 | 37 | 15.04 | 64 | 14.31 | 57 | 12.7 (28.3) | ||
| 74 | 50.39 | 71 | 52.08 | 145 | 51.20 | 273 | 96.4 (185.9) | ||
| 79 | 141.35 | 89 | 186.31 | 168 | 162.07 | 365 | 352.1 (653.1) | ||
| 57 | 298.15 | 68 | 415.20 | 125 | 352.16 | 218 | 614.2 (1140.3) | ||
| 13 | 259.71 | 19 | 288.07 | 32 | 275.84 | 61 | 525.8 (1218.7) | ||
| 22 | 3.07 | 12 | 1.62 | 34 | 2.34 | 105 | 7.2 (14.6) | ||
| 130 | 17.80 | 155 | 17.29 | 285 | 17.52 | 346 | 21.3 (47.4) | ||
| 396 | 75.98 | 442 | 90.90 | 838 | 83.19 | 1440 | 142.9 (276.3) | ||
| 388 | 201.05 | 414 | 248.16 | 802 | 222.89 | 1479 | 411.0 (766.4) | ||
| 292 | 434.25 | 282 | 511.75 | 574 | 469.15 | 982 | 802.6 (1460.4) | ||
| 94 | 560.00 | 88 | 413.99 | 182 | 478.41 | 280 | 736.0 (1668.1) | ||
| 3 | 2 | 5 | - | 6 | - | ||||
Reported LE severity and acute attacks summary.
| Mild (stage 1–2) | Moderate (stage 3–4) | Severe (stage 5+) | Total | ||
|---|---|---|---|---|---|
| 319 | 260 | 193 | 772 | ||
| 41.3% | 33.7% | 25.0% | 100% | ||
| 1.67 | 2.06 | 2.83 | 1.75 | ||
| 1.51 | 2.00 | 2.00 | 1.89 | ||
| 350 | 325 | 244 | 919 | ||
| 38.1% | 36.5% | 26.6% | 100% | ||
| 1.16 | 1.71 | 2.39 | 1.51 | ||
| 1.08 | 1.15 | 1.72 | 1.50 | ||
| 106 | 208 | 141 | 455 | ||
| 23.3% | 45.7% | 31.0% | 100% | ||
| 0.99 | 1.53 | 2.30 | 1.45 | ||
| 1.28 | 1.65 | 1.78 | 1.65 | ||
| 775 | 793 | 578 | 2146 | ||
| 36.1% | 37.0% | 26.9% | 100% | ||
| 1.34 | 1.78 | 2.52 | 1.58 | ||
| 1.33 | 1.62 | 1.84 | 1.68 |
Fig 2(a) Population density at the ward level for 2015 using extrapolated data from 2012 census, and the reported morbidity prevalence per 100,000 people obtained using the MeasureSMS-Morbidity system (b) overall,(c) for LE and (d) for hydrocoele.
Summary of messages received during the patient identification period.
| Temeke | Kinondoni | Ilala | ||||
|---|---|---|---|---|---|---|
| N | % | N | % | N | % | |
| 118 | 148 | 92 | ||||
| 600 | 500 | 400 | ||||
| 12 | - | 15 | 12 | |||
| 3126 | - | 3594 | 1885 | - | ||
| 2980 | 95.3% | 2945 | 82.9% | 1527 | 81.0% | |
| 2588 | 82.8% | 3006 | 83.6% | 1588 | 84.2% | |
| 2550 | 98.5% | 2846 | 94.7% | 1493 | 94.0% | |
Fig 3SMS acceptance rates over the patient identification period by day of reporting for each district.
Verification data summaries.
Note that the reported lymphoedema-elephantiasis and hydrocoele rows include those who were reported to have both conditions. The report was considered to be correct if the patient was confirmed to have the reported condition, regardless of whether or not another LF-related condition was also reported or confirmed.
| Temeke | Kinondoni | Ilala | Total | |
|---|---|---|---|---|
| Reported | 15 | 27 | 39 | 81 |
| Correct | 13 | 22 | 28 | 63 |
| % Correct | 86.7% | 81.5% | 71.8% | 77.8% |
| Reported | 21 | 74 | 84 | 179 |
| Correct | 20 | 71 | 74 | 165 |
| % Correct | 95.2% | 95.9% | 88.1% | 92.2% |
A comparison of reported and verified lymphoedema-elephantiasis severity.
| 3 | 8 | 0 | 11 | ||
| 8 | 16 | 2 | 26 | ||
| 4 | 13 | 6 | 23 | ||
| 15 | 37 | 8 | 60 | ||